Immune stroma in lung cancer and idiopathic pulmonary fibrosis: A common biologic landscape?

Research output: Contribution to journalReview articlepeer-review


Idiopathic pulmonary fibrosis (IPF) identifies a specific entity characterized by chronic, progressive fibrosing interstitial pneumonia of unknown cause, still lacking effective therapies. Growing evidence suggests that the biologic processes occurring in IPF recall those which orchestrate cancer onset and progression and these findings have already been exploited for therapeutic purposes. Notably, the incidence of lung cancer in patients already affected by IPF is significantly higher than expected. Recent advances in the knowledge of the cancer immune microenvironment have allowed a paradigm shift in cancer therapy. From this perspective, recent experimental reports suggest a rationale for immune checkpoint inhibition in IPF. Here, we recapitulate the most recent knowledge on lung cancer immune stroma and how it can be translated into the IPF context, with both diagnostic and therapeutic implications.

Original languageEnglish
Article number2882
Pages (from-to)1-16
Number of pages16
JournalInternational Journal of Molecular Sciences
Issue number6
Publication statusPublished - Mar 2 2021


  • Cancer
  • Fibrosis
  • Genetics
  • Immune system
  • Microenvironment
  • Targeted therapy

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Immune stroma in lung cancer and idiopathic pulmonary fibrosis: A common biologic landscape?'. Together they form a unique fingerprint.

Cite this